Literature DB >> 18419421

Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network.

Kevin L Winthrop1, S Yamashita, S E Beekmann, P M Polgreen.   

Abstract

We present the results of a nationwide survey of infectious disease consultants to identify mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor compounds and other novel targeted therapies. Nontuberculous mycobacterial infections, histoplasmosis, and invasive Staphylococcus aureus infection were all reported more frequently than was tuberculosis disease in this context.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18419421     DOI： 10.1086/587989

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  41 in total

Review 1.  Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy.

Authors:  Kevin L Winthrop; Michael Iseman
Journal:  Nat Rev Rheumatol       Date:  2013-06-25       Impact factor: 20.543

2.  [Recommendations for use of rituximab in patients with rheumatoid arthritis].

Authors:  A Rubbert-Roth; G R Burmester; T Dörner; A Gause
Journal:  Z Rheumatol       Date:  2014-03       Impact factor: 1.372

Review 3.  Preventing and treating biologic-associated opportunistic infections.

Authors:  Kevin L Winthrop; Tom Chiller
Journal:  Nat Rev Rheumatol       Date:  2009-07       Impact factor: 20.543

4.  The reliability of diagnostic coding and laboratory data to identify tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients using anti-tumor necrosis factor therapy.

Authors:  Kevin L Winthrop; Roger Baxter; Liyan Liu; Bentson McFarland; Donald Austin; Cara Varley; LeAnn Radcliffe; Eric Suhler; Dongsoek Choi; Lisa J Herrinton
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-12-10       Impact factor: 2.890

5.  The Infectious Diseases Society of America emerging infections network: bridging the gap between clinical infectious diseases and public health.

Authors:  Satish K Pillai; Susan E Beekmann; Scott Santibanez; Philip M Polgreen
Journal:  Clin Infect Dis       Date:  2014-01-07       Impact factor: 9.079

6.  Patient-Centered Research Priorities for Pulmonary Nontuberculous Mycobacteria (NTM) Infection. An NTM Research Consortium Workshop Report.

Authors:  Emily Henkle; Timothy Aksamit; Alan Barker; Charles L Daley; David Griffith; Philip Leitman; Amy Leitman; Elisha Malanga; Theodore K Marras; Kenneth N Olivier; D Rebecca Prevots; Delia Prieto; Alexandra L Quittner; William Skach; John W Walsh; Kevin L Winthrop
Journal:  Ann Am Thorac Soc       Date:  2016-09

7.  TNF-alpha is a positive regulatory factor for human Vgamma2 Vdelta2 T cells.

Authors:  Haishan Li; Kun Luo; C David Pauza
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

8.  Management of pulmonary nontuberculous mycobacterial disease.

Authors:  Kathleen L Horan; Shawn J Skerrett
Journal:  F1000 Med Rep       Date:  2009-12-15

Review 9.  Rationale of using different biological therapies in rheumatoid arthritis.

Authors:  Matthias Geyer; Ulf Müller-Ladner
Journal:  Arthritis Res Ther       Date:  2010-08-24       Impact factor: 5.156

Review 10.  Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy.

Authors:  Kevin L Winthrop; Eric Chang; Shellie Yamashita; Michael F Iademarco; Philip A LoBue
Journal:  Emerg Infect Dis       Date:  2009-10       Impact factor: 6.883
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.